Lavipharm S.A. (LAVI.AT)
EUR 0.75
(-1.7%)
EUR 0.75
(-1.7%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 539 Thousand | 3.36 Million | 3.84 Million | 2.85 Million | 2.89 Million | 1.43 Million |
| Net Income | 1.99 Million | 953 Thousand | 1.72 Million | 2.09 Million | 5.32 Million | 1.24 Million |
| Depreciation & Amortization | 4.35 Million | 1.7 Million | 1.65 Million | 1.56 Million | 1.42 Million | 1.18 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -6.92 Million | -3.35 Million | -3.49 Million | -3.71 Million | -1.67 Million | -1.78 Million |
| Other non-cash items | 16.79 Million | 11 Million | 10.65 Million | 9.17 Million | 1.77 Million | 4.63 Million |
| Investing Cash Flow | -3.71 Million | -35.61 Million | -1.9 Million | -1.47 Million | -2.41 Million | -1.03 Million |
| Investments in PPE | -4.11 Million | -35.61 Million | -1.91 Million | -1.47 Million | -2.41 Million | -1.03 Million |
| Acquisitions | 405 Thousand | 4000.00 | 12 Thousand | - | 2000.00 | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -1000.00 | - | - | - | - | - |
| Financing Cash Flow | -6.63 Million | 48.84 Million | -2.23 Million | -1.17 Million | -595 Thousand | -904 Thousand |
| Debt repayment | -4.98 Million | -263 Thousand | -2.23 Million | -1.17 Million | -595 Thousand | -904 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -2.49 Million | - | - | - | - | - |
| Common Stock Issuance | - | 49.28 Million | - | - | - | - |
| Other Financing Activities | 2.03 Million | - | - | - | - | - |
| Accounts receivables | -4.56 Million | -76 Thousand | -3.38 Million | 329 Thousand | -1.5 Million | -1.26 Million |
| Accounts payables | 2.48 Million | -1.51 Million | 749 Thousand | -1.11 Million | 1.66 Million | -945 Thousand |
| Inventory | -4.89 Million | -1.94 Million | -753 Thousand | -2.34 Million | -1.25 Million | 724 Thousand |
| Other working capital | 45 Thousand | 177 Thousand | -100 Thousand | -591 Thousand | -565 Thousand | -290 Thousand |
| Cash at beginning of period | 18.24 Million | 1.63 Million | 1.93 Million | 1.73 Million | 1.84 Million | 2.34 Million |
| Cash at end of period | 8.43 Million | 18.24 Million | 1.63 Million | 1.93 Million | 1.73 Million | 1.84 Million |
| Capital Expenditure | -4.11 Million | -35.61 Million | -1.91 Million | -1.47 Million | -2.41 Million | -1.03 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -9.8 Million | 16.6 Million | -294 Thousand | 200 Thousand | -110 Thousand | -506 Thousand |
| Free Cash Flow | -3.57 Million | -32.24 Million | 1.92 Million | 1.37 Million | 483 Thousand | 398 Thousand |
| Breakdown | 2024 Q2 | 2023 FY | 2023 Q4 | 2023 Q2 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 7.4 Million | 1.99 Million | -220 Thousand | 2.21 Million | 953 Thousand | -1.06 Million |
| Depreciation & Amortization | 2.15 Million | 4.35 Million | 2.15 Million | 2.19 Million | 1.7 Million | 894 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -2.62 Million | -6.92 Million | -3.3 Million | -3.62 Million | -3.35 Million | -2.33 Million |
| Other non-cash items | -3.24 Million | 16.79 Million | 7.92 Million | 8.86 Million | 11 Million | 7.5 Million |
| Investing Cash Flow | -3.4 Million | -3.71 Million | -2.49 Million | -1.21 Million | -35.61 Million | -35.11 Million |
| Investments in PPE | -3.39 Million | -4.11 Million | -2.9 Million | -1.21 Million | -35.61 Million | -35.33 Million |
| Acquisitions | - | 405 Thousand | 405 Thousand | - | 4000.00 | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -1000.00 | -1000.00 | - | - | - | - |
| Financing Cash Flow | -31 Thousand | -6.63 Million | -2.4 Million | -4.23 Million | 48.84 Million | 49.56 Million |
| Debt repayment | -361 Thousand | -4.98 Million | -3.54 Million | -1.44 Million | -263 Thousand | -979 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -2.49 Million | -67 Thousand | -2.42 Million | - | - |
| Common Stock Issuance | - | - | - | - | 49.28 Million | 49.28 Million |
| Other Financing Activities | -392 Thousand | 2.03 Million | 2.03 Million | - | - | - |
| Accounts receivables | -1.12 Million | -4.56 Million | -2.11 Million | -2.45 Million | -76 Thousand | -342 Thousand |
| Accounts payables | 303 Thousand | 2.48 Million | 156 Thousand | 2.33 Million | -1.51 Million | -2.07 Million |
| Inventory | -1.8 Million | -4.89 Million | -1.35 Million | -3.53 Million | -1.94 Million | 266 Thousand |
| Other working capital | -1000.00 | 45 Thousand | 13 Thousand | 32 Thousand | 177 Thousand | -183 Thousand |
| Cash at beginning of period | 8.43 Million | 18.24 Million | 14.4 Million | 18.24 Million | 1.63 Million | 2.74 Million |
| Cash at end of period | 8.68 Million | 8.43 Million | 8.43 Million | 14.4 Million | 18.24 Million | 18.24 Million |
| Capital Expenditure | -3.39 Million | -4.11 Million | -2.9 Million | -1.21 Million | -35.61 Million | -35.33 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 253 Thousand | -9.8 Million | -5.97 Million | -3.83 Million | 16.6 Million | 15.5 Million |
| Free Cash Flow | 285 Thousand | -3.57 Million | -3.97 Million | 394 Thousand | -32.24 Million | -34.28 Million |
300345
BTAFF
6806
CTPNV
2327
UCASU